188 related articles for article (PubMed ID: 38479746)
1. Assessing the acceptability of, adherence to and preference for a dual prevention pill (DPP) for HIV and pregnancy prevention compared to oral pre-exposure prophylaxis (PrEP) and oral contraception taken separately: protocols for two randomised, controlled, cross-over studies in South Africa and Zimbabwe.
Friedland BA; Mgodi NM; Palanee-Phillips T; Mathur S; Plagianos MG; Bruce IV; Lansiaux M; Murombedzi C; Musara P; Dandadzi A; Reddy K; Ndlovu N; Zulu SK; Shale LR; Zieman B; Haddad LB
BMJ Open; 2024 Mar; 14(3):e075381. PubMed ID: 38479746
[TBL] [Abstract][Full Text] [Related]
2. Alignment of PrEP adherence with periods of HIV risk among adolescent girls and young women in South Africa and Zimbabwe: a secondary analysis of the HPTN 082 randomised controlled trial.
Velloza J; Donnell D; Hosek S; Anderson PL; Chirenje ZM; Mgodi N; Bekker LG; Marzinke MA; Delany-Moretlwe S; Celum C
Lancet HIV; 2022 Oct; 9(10):e680-e689. PubMed ID: 36087612
[TBL] [Abstract][Full Text] [Related]
3. Protocol for a longitudinal study to evaluate the use of tenofovir-based PrEP for safer conception and pregnancy among women in South Africa.
Matthews LT; Jaggernath M; Kriel Y; Smith PM; O'Neil K; Haberer JE; Hendrix C; Baeten JM; Ware NC; Wirth K; Psaros C; Bangsberg DR; Smit JA
BMJ Open; 2019 Jul; 9(7):e027227. PubMed ID: 31350241
[TBL] [Abstract][Full Text] [Related]
4. Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial.
Gill K; Johnson L; Dietrich J; Myer L; Marcus R; Wallace M; Pidwell T; Mendel E; Fynn L; Jones K; Wiesner L; Slack C; Strode A; Spiegel H; Hosek S; Rooney J; Gray G; Bekker LG
Lancet Child Adolesc Health; 2020 Dec; 4(12):875-883. PubMed ID: 33222803
[TBL] [Abstract][Full Text] [Related]
5. Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover trial.
Nair G; Celum C; Szydlo D; Brown ER; Akello CA; Nakalega R; Macdonald P; Milan G; Palanee-Phillips T; Reddy K; Tahuringana E; Muhlanga F; Nakabiito C; Bekker LG; Siziba B; Hillier SL; Baeten JM; Garcia M; Johnson S; McClure T; Levy L; Livant E; Jacobson C; Soto-Torres L; van der Straten A; Hosek S; Rooney JF; Steytler J; Bunge K; Parikh U; Hendrix C; Anderson P; Ngure K;
Lancet HIV; 2023 Dec; 10(12):e779-e789. PubMed ID: 37898146
[TBL] [Abstract][Full Text] [Related]
6. PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trial.
Celum C; Hosek S; Tsholwana M; Kassim S; Mukaka S; Dye BJ; Pathak S; Mgodi N; Bekker LG; Donnell DJ; Wilson E; Yuha K; Anderson PL; Agyei Y; Noble H; Rose SM; Baeten JM; Fogel JM; Adeyeye A; Wiesner L; Rooney J; Delany-Moretlwe S
PLoS Med; 2021 Jun; 18(6):e1003670. PubMed ID: 34143779
[TBL] [Abstract][Full Text] [Related]
7. Baseline preferences for oral pre-exposure prophylaxis (PrEP) or dapivirine intravaginal ring for HIV prevention among adolescent girls and young women in South Africa, Uganda and Zimbabwe (MTN-034/IPM-045 study).
Ngure K; Friedland BA; Szydlo DW; Roberts ST; Garcia M; Levy L; Akello CA; Reddy K; Palanee-Phillips T; Macdonald P; Siziba B; Soto-Torres L; Hosek S; Hillier SL; Nair G; Celum C; van der Straten A
PLoS One; 2023; 18(6):e0287525. PubMed ID: 37352296
[TBL] [Abstract][Full Text] [Related]
8. The Community PrEP Study: a randomized control trial leveraging community-based platforms to improve access and adherence to pre-exposure prophylaxis to prevent HIV among adolescent girls and young women in South Africa-study protocol.
Medina-Marino A; Bezuidenhout D; Hosek S; Barnabas RV; Atujuna M; Bezuidenhout C; Ngwepe P; Peters RPH; Little F; Celum CL; Daniels J; Bekker LG
Trials; 2021 Jul; 22(1):489. PubMed ID: 34311754
[TBL] [Abstract][Full Text] [Related]
9. How a menu of adherence support strategies facilitated high adherence to HIV prevention products among adolescent girls and young women in sub-Saharan Africa: a mixed methods analysis.
Roberts ST; Mancuso N; Williams K; Nabunya HK; Mposula H; Mugocha C; Mvinjelwa P; Garcia M; Szydlo DW; Soto-Torres L; Ngure K; Hosek S
J Int AIDS Soc; 2023 Nov; 26(11):e26189. PubMed ID: 37936551
[TBL] [Abstract][Full Text] [Related]
10. Strengthening health system's capacity for pre-exposure prophylaxis for adolescent girls and young women and adolescent boys and young men in South Africa (SHeS'Cap-PrEP): Protocol for a mixed methods study in KwaZulu-Natal, South Africa.
Nicol E; Ramraj T; Hlongwa M; Basera W; Jama N; Lombard C; McClinton-Appollis T; Govindasamy D; Pass D; Funani N; Aheron S; Paredes-Vincent A; Drummond J; Cheyip M; Dladla S; Bedford J; Mathews C
PLoS One; 2022; 17(3):e0264808. PubMed ID: 35298487
[TBL] [Abstract][Full Text] [Related]
11. Combined HIV Adolescent Prevention Study (CHAPS): comparison of HIV pre-exposure prophylaxis regimens for adolescents in sub-Saharan Africa-study protocol for a mixed-methods study including a randomised controlled trial.
Nash S; Dietrich J; Ssemata AS; Herrera C; O'Hagan K; Else L; Chiodi F; Kelly C; Shattock R; Chirenje M; Lebina L; Khoo S; Bekker LG; Weiss HA; Gray C; Stranix-Chibanda L; Kaleebu P; Seeley J; Martinson N; Fox J;
Trials; 2020 Oct; 21(1):900. PubMed ID: 33121503
[TBL] [Abstract][Full Text] [Related]
12. A qualitative study to explore daily versus on-demand oral pre-exposure prophylaxis (PrEP) in young people from South Africa, Uganda and Zimbabwe.
Dietrich JJ; Ahmed N; Tshabalala G; Wu M; Mulaudzi M; Hornschuh S; Atujuna M; Muhumuza R; Ssemata AS; Stranix-Chibanda L; Nematadzira T; Bekker LG; Martinson N; Seeley J; Fox J
PLoS One; 2023; 18(6):e0287627. PubMed ID: 37384792
[TBL] [Abstract][Full Text] [Related]
13. Stepped care to optimize pre-exposure prophylaxis (PrEP) effectiveness in pregnant and postpartum women (SCOPE-PP) in South Africa: a randomized control trial.
Joseph Davey DL; Dovel K; Cleary S; Khadka N; Mashele N; Silliman M; Mvududu R; Nyemba DC; Coates TJ; Myer L
BMC Public Health; 2022 Jul; 22(1):1306. PubMed ID: 35799121
[TBL] [Abstract][Full Text] [Related]
14. A multi-country cross-sectional study to assess predictors of daily versus on-demand oral pre-exposure prophylaxis in youth from South Africa, Uganda and Zimbabwe.
Dietrich JJ; Ahmed N; Webb EL; Tshabalala G; Hornschuh S; Mulaudzi M; Atujuna M; Stranix-Chibanda L; Nematadzira T; Ssemata AS; Muhumuza R; Seeley J; Bekker LG; Weiss HA; Martinson N; Fox J;
J Int AIDS Soc; 2022 Aug; 25(8):e25975. PubMed ID: 36002910
[TBL] [Abstract][Full Text] [Related]
15. The influence of HIV-related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: a qualitative study.
Velloza J; Khoza N; Scorgie F; Chitukuta M; Mutero P; Mutiti K; Mangxilana N; Nobula L; Bulterys MA; Atujuna M; Hosek S; Heffron R; Bekker LG; Mgodi N; Chirenje M; Celum C; Delany-Moretlwe S;
J Int AIDS Soc; 2020 Mar; 23(3):e25463. PubMed ID: 32144874
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of the dual prevention pill for contraception and HIV pre-exposure prophylaxis.
Milali MP; Resar D; Kaftan D; Campbell J; Olowu A; Edwards D; Platais I; Kim HY; Jenkins S; Bershteyn A
Front Reprod Health; 2023; 5():1144217. PubMed ID: 37266447
[TBL] [Abstract][Full Text] [Related]
17. "It's already in your body and it's preventing": a qualitative study of African female adolescent's acceptability and preferences for proxy HIV prevention methods in Cape Town, South Africa.
Fynn L; Gill K; Wallace M; Atujuna M; Duyver M; Ngcobo P; Spiegel H; Rinehart A; Hosek S; Bekker LG
BMC Public Health; 2023 Nov; 23(1):2143. PubMed ID: 37919697
[TBL] [Abstract][Full Text] [Related]
18. Adaptive HIV pre-exposure prophylaxis adherence interventions for young South African women: Study protocol for a sequential multiple assignment randomized trial.
Velloza J; Poovan N; Ndlovu N; Khoza N; Morton JF; Omony J; Mkwanazi E; Grabow C; Donnell D; Munthali R; Baeten JM; Hosek S; Celum C; Delany-Moretlwe S
PLoS One; 2022; 17(4):e0266665. PubMed ID: 35417485
[TBL] [Abstract][Full Text] [Related]
19. Acceptability of a long-acting injectable HIV prevention product among US and African women: findings from a phase 2 clinical Trial (HPTN 076).
Tolley EE; Li S; Zangeneh SZ; Atujuna M; Musara P; Justman J; Pathak S; Bekker LG; Swaminathan S; Stanton J; Farrior J; Sista N
J Int AIDS Soc; 2019 Oct; 22(10):e25408. PubMed ID: 31651098
[TBL] [Abstract][Full Text] [Related]
20. Integrated provision of topical pre-exposure prophylaxis in routine family planning services in South Africa: a non-inferiority randomized controlled trial.
Mansoor LE; Yende-Zuma N; Baxter C; Mngadi KT; Dawood H; Gengiah TN; Samsunder N; Schwartz JL; Doncel GF; Abdool Karim Q
J Int AIDS Soc; 2019 Sep; 22(9):e25381. PubMed ID: 31507088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
